Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 1 Diabetes Mellitus

In brief

The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.

Key facts

Study ID

NCT02268214

Run by

AstraZeneca

People needed

833

Starts

2014-11-11

Expected to finish

2017-08-25

Last updated by the study team

2018-09-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Type 1 Diabetes mellitus (T1DM)
• Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)
• Insulin use for at least 12 months per patient reported or medical records
• Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to screening
• Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to screening
• If on MDI insulin administration, subject must be on ≥ 3x injections per day
• Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%
• Body mass index (BMI) ≥ 18.5 kg/m2

You may not qualify if…

• History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased beta cell capacity
• Taking metformin and/or thiazolidinediones within 2 months prior to screening
• Taking any antidiabetic medication (other than insulin), within 1 month prior to screening
• Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly administration and within 1 month prior to screening for once or twice daily administration
• History of diabetes ketoacidosis requiring medical intervention within 1 month prior to screening
• History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to screening
• Frequent episodes of severe hypoglycemia (more than one episode requiring medical assistance, emergency care), and/or glucagon therapy administered by a third-party individual within 1 month prior to screening
• History of Addison's disease

Where it is running

• Research Site — Encino, California, United States
• Research Site — La Mesa, California, United States
• Research Site — San Diego, California, United States
• Research Site — Tarzana, California, United States
• Research Site — Torrance, California, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Denver, Colorado, United States
• Research Site — Cooper City, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Port Orange, Florida, United States
• Research Site — Idaho Falls, Idaho, United States
• Research Site — Des Moines, Iowa, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Portland, Maine, United States
• Research Site — Hyattsville, Maryland, United States
• Research Site — Rockville, Maryland, United States
• Research Site — Kalamazoo, Michigan, United States
• Research Site — Minneapolis, Minnesota, United States
• Research Site — Chesterfield, Missouri, United States
• Research Site — Las Vegas, Nevada, United States
• Research Site — Albany, New York, United States
• Research Site — Buffalo, New York, United States
• Research Site — Asheville, North Carolina, United States
• Research Site — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.